# US 2016/0354486 A1 · Binding molecule conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354486 A1
- Document ID: US20160354486A1
- Status: Published application
- Kind: A1
- Application number: 14/979,114
- Filed: 2015-12-22
- Published: 2016-12-08
- Earliest claimed: 2012-01-20
- Assignees: Sea Lane Biotechnologies, LLC
- Applicants: Sea Lane Biotechnologies, LLC
- Inventors: Lawrence C. Horowitz; Ramesh R. Bhatt; Charles H. Hannum; Pamela K. Foreman; Danying Cai; Medini Gore; Li Xu; Phil Kobel
- Web page: https://patentgrep.com/patent/US20160354486A1

## CPC

- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 38/05: Dipeptides
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6881: {Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other}
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/32: against translation products of oncogenes
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention concerns methods for identifying, producing, and engineering binding molecule conjugates, and to the conjugates produced. In particular, the invention concerns Surrobody conjugates composed of an antibody heavy chain variable domain and a surrogate light chain, wherein the surrogate light chain and/or the antibody heavy chain variable domain is conjugated to a therapeutic or diagnostic agent.

## Claims

### Claim at position 1

1-38. (canceled)

### Claim 39

A binding molecule conjugate comprising a surrogate light chain (SLC) polypeptide having at least one agent linked to an amino acid residue of the SLC polypeptide at a predetermined amino acid position, wherein the amino acid residue is either
(i) normally present in the SLC polypeptide at said amino acid position, or
(ii) introduced into the amino acid sequence of said SLC polypeptide at said amino acid position, wherein the agent is a therapeutic agent, and wherein the therapeutic agent is selected from the group consisting of a maytansinoid, a monomethyl auristatin E (MMAE) and a monomethyl auristatin F (MMAF).

### Claim at position 3

40-48. (canceled)

### Claim 49

A surrogate light chain construct comprising:
a heavy chain variable domain; and
a surrogate light chain (SLC) having at least one amino acid residue at a predetermined amino acid position for conjugation to an agent, wherein the amino acid residue is located
(i) at a 16th and/or 21st position of an amino acid sequence of a VpreB1 from which a secretory leader is absent; and/or
(ii) at one or more positions selected from the group consisting of a 60th, 74th, 78th, 79th, 85th, 91st, 110th, 123rd, 131st, 133rd, 166th, and 170th position of an amino acid sequence of a λ5 from which a secretory leader is absent,
wherein the heavy chain variable domain and SLC comprise a binding region.

### Claim 50 (depends on 49)

The surrogate light chain construct of claim 49, wherein said at least one amino acid residue is introduced into the predetermined amino acid position of the SLC.

### Claim 51 (depends on 50)

The surrogate light chain construct of claim 50, wherein the at least one amino acid residue is in the predetermined amino acid position of the SLC by a substitution.

### Claim 52 (depends on 50)

The surrogate light chain construct of claim 50, wherein the at least one amino acid residue is a cysteine or a lysine.

### Claim 53 (depends on 51)

The surrogate light chain construct of claim 51, wherein the at least one amino acid residue is a cysteine or a lysine.

### Claim 54 (depends on 49)

The surrogate light chain construct of claim 49, wherein the SLC comprises a fusion of a λ5 sequence to a heterologous amino acid sequence, wherein said heterologous amino acid sequence comprises an antibody light chain variable region sequence.

### Claim 55 (depends on 54)

The surrogate light chain construct of claim 54, wherein said at least one amino acid residue is introduced into the amino acid sequence of the λ5 sequence.

### Claim 56 (depends on 55)

The surrogate light chain construct of claim 55, wherein the at least one amino acid residue is in the amino acid sequence of the λ5 sequence by a substitution.

### Claim 57 (depends on 55)

The surrogate light chain construct of claim 55, wherein the at least one amino acid residue is a cysteine or a lysine.

### Claim 58 (depends on 56)

The surrogate light chain construct of claim 56, wherein the at least one amino acid residue is a cysteine or a lysine.

### Claim 59 (depends on 39)

The binding molecule conjugate of claim 39, wherein the surrogate light chain (SLC) having at least one amino acid residue at the predetermined amino acid position is for conjugation to at least one of maytansinoids and maytansinoid analogs, benzodiazepines, taxoids, CC-1065 and CC-1065 analogs, duocarmycins and duocarmycin analogs, enediynes, such as calicheamicins, dolastatin and dolastatin analogs including auristatins, tomaymycin derivatives, leptomycin derivatives, methotrexate, cisplatin, carboplatin, daunorubicin, doxorubicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil and morpholino doxorubicin.
